Westaim Corp has announced an initial public offering (IPO) for its subsidiary NUCRYST Pharmaceuticals Corp, which develops medical products based on its nanocrystalline silver technology. The IPO is open to Canadian and US investors, with shares offered by an underwriting team led by Jeffries and Co Ltd. Westaim will retain a controlling interest in NUCRYST.